Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

New approach to inhibiting thrombin-induced neuronal cell death

Dec. 29, 1999

Update on preclinical and clinical testing of R.W. Johnson's fibrinogen antagonist

Dec. 27, 1999

Recently issued patent covers Berlex's new anticoagulants

Dec. 23, 1999

Selective, orally active factor Xa inhibitors designed by JT scientists

Dec. 22, 1999

Meiji Seika presents heterocyclic inhibitors of platelet aggregation

Dec. 22, 1999

Orally active antiplatelet agents derived from isoquinolone leads at Lilly

Dec. 21, 1999

Hungarian team describes novel orally active antithrombotic agents

Dec. 21, 1999

Efficacy and mechanism of action of DX-9065a in experimental DIC in rats

Dec. 21, 1999

New antiplatelet pyridazinones presented by Chinese university investigators

Dec. 20, 1999

Emisphere Technologies to begin phase III oral heparin program

Dec. 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...